Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects

Muscle and Nerve

Volumn 27, Issue 4, 2003, Pages 407-425

  Mastaglia, Frank L ^a,b   Garlepp, Michael J ^c   Phillips, Beverley A ^d   Zilko, Paul J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical features; Dermatomyositis; Diagnosis; Inclusion body myositis; Inflammatory myopathies; Polymyositis; Treatment

Indexed keywords

ALPHA INTERFERON; ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; DEXAMETHASONE; FLUDARABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFLUMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; PROCAINAMIDE; QUINIDINE; SIMVASTATIN; STEROID; TACROLIMUS; TRYPTOPHAN; UNINDEXED DRUG;

ANTIBODY SPECIFICITY; CANCER; CANCER SCREENING; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; DRUG SELECTIVITY; EMPIRICISM; EOSINOPHIL; EPIDEMIOLOGICAL DATA; EXERCISE; GENETICS; GRANULOMATOSIS; HISTOPATHOLOGY; HUMAN; IMAGING; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; INFLAMMATION; MACROPHAGE; MICROANGIOPATHY; MOLECULAR MECHANICS; MUSCLE BIOPSY; MUSCLE INJURY; MYOPATHY; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASITISM; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RELAPSE; RETROVIRUS INFECTION; REVIEW; STEROID THERAPY;

ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MUSCLE, SKELETAL; MYOSITIS;

EID: 0037381381     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10313     Document Type: Review

References (256)

1. Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997;109:275-285.
2. Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, McGarvey C, Sonies BC, Bartlett ML, Villalba ML, Fleisher T, Plotz PH. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of end-point measures. J Rheumatol 1999;26:352-360.
3. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300-1303.
4. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-648.
5. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;444:1516-1518.
6. Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, Barohn RJ. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-586.
7. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies: III. Immunoelectronmicroscopy aspects of cell-mediates muscle fibre injury. Ann Neurol 1988;19:112-125.
8. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000;13:541-545.
9. Argov A, Mastaglia FL. Drug-induced neuromuscular disorders in man. In: Walton J, Karpati G, Hilton-Jones D, editors. Disorders of voluntary muscle, 6th ed. Edinburgh: Churchill Livingstone; 1994. p 989-1029.
10. Askanas V, Engel WK. Does overexpression of bAPP in aging muscle have a pathogenic role in a relevance to Alzheimer's disease: clues from inclusion body myositis, cultured human muscle and transgenic mice. Am J Pathol 1998;153:1673-1677.
11. Askanas V, Alvarez RB, Mirabella M, Engel WK. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion body myositis. Ann Neurol 1996;39:389-391.
12. Authier FJ, Kondo H, Ghnassia RT, Revuz J, Gherardi RK. Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology 1996;46:1448-1451.
13. Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Howeler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55:1385-1387.
14. Badrising UA, Maat-Schieman M, Ferrari MD, Zwinderman AH, Wessels JAM, Breedveld FC, van Doorn PA, van Engelen BGM, Hoogendijk JE, Howeler CJ, de Jager AE, Jennekens FGI, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372.
15. Banker BQ. Dermatomyositis of childhood. Ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol 1975;34:46-75.
16. Barkhaus PE, Periquet MI, Nandedikar SD. Quantitative electrophysiologic studies in sporadic inclusion body myositis. Muscle Nerve 1999;22:480-487.
17. Barnes BE. Dermatomyositis and malignancy. Ann Intern Med 1976;84:68-76.
18. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to therapy. Neurology 1995;45:1302-1304.
19. Baron P, Galimberti D, Meda L, Scarpini E, Conti G, Cogiamanian F, Scarlato, G. Production of IL-6 by human myoblasts stimulated with Aβ relevance in the pathogenesis of IBM. Neurology 2001;57:1561-1565.
20. Bartoccioni E, Michaelis D, Hohlfeld R. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett 1994;42:135-138.
21. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibers and inflammatory cells. Brain 1997;120:929-938.
22. Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998;161:5943-5951.
23. Belongia EA, Hedberg CW, Gleich GJ, White KE, Mayeno AN, Loegering DA, Dunnette SL, Pirie PL, MacDonald KL, Osterholm MT. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357-365.
24. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998;84:86-91.
25. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-347.
26. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 paients with polymyositis and dermatomyositis. Medicine 1977;86:255-286.
27. Bombardieri S, Hughes GRV, Neri R, Del Bravo P, Del Bono L. Cyclophosphamide in severe polymyositis. Lancet 1989;1:1138-1139.
28. Brouwer R, Hengstman GJD, Egberts WV, Ehrfeld H, Bozic B, Chirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundbert I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BGM, van Venrooij WJ. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-123.
29. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001;134:1087-1095.
30. Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow up. Arthritis Rheum 1981;24:45-48.
31. Bunch TW, Worthington JW, Coombs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980;92:365-369.
32. Callen JP. Dermatomyositis. Lancet 2000;355:53-57.
33. Carroll GJ, Will RK, Peter JB, Garlepp MJ, Dawkins RL. Penicillamine induced polymyositis and dermatomyositis. J Rheumatol 1987;14:995-999.
34. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
35. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-831.
36. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P. Efficacy of intravenous gamma-globulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91:162-168.
37. Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, Godeau P, Herson S. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994;21:1092-1097.
38. Cherin P, Menard D, Mouton P, Viallard JF, LeHello C, Authier FJ, Gherardi RK, Coquet M, Herson S, Leroi JP. Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases. Neuromuscul Disord 2001; 11:452-457.
39. Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-474.
40. Cherin P, Pelletier S, Teixeira A, Laforet P, Simon A, Herson S, Eymard B. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326-327.
41. Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002;41:7-13.
42. Ciafaloni E, Massey JM, Tucker-Lipsomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-99.
43. Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, Paulus HE. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum 1978;21:62-71.
44. Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000;59:164-169.
45. Cronin ME, Plotz PH. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1990;16:655-665.
46. Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathies. J Rheumatol 1989; 16:1225-1228.
47. Csuka M, McCarty DJ. Simple method for measurement of lower extremity muscle strength. Am J Med 1985;78:77-81.
48. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
49. Dabby R, Lange DJ, Trojaborg W, Hays AP, Lovelace RE, Brannagan TH, Rowland LP. Inclusion body myositis mimicking motor neuron disease. Arch Neurol 2001;58:1253-1256.
50. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991;325:1487-1498.
51. Dalakas MC. Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg 1992;5:645-654.
52. Dalakas MC. Retroviruses and inflammatory myopathies in humans and primates. Baillieres Clin Neurol 1993;2:659-691.
53. Dalakas MC. Controlled studies of high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 1998; 51 (suppl 5):S37-S45.
54. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998;54:1509-1512.
55. Dalakas MC. Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry 2001;70: 569-573.
56. Dalakas M, Illa I, Dambrosia J, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
57. Dalakas M, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 1997;41:100-104.
58. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind placebo-controlled study. Neurology 1997;48:712-716.
59. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327.
60. Danon MJ, Perurena OH, Ronan S, Manaligod JR. Inclusion body myositis associated with systemic sarcoidosis. Can J Neurol Sci 1986;13:334-336.
61. D'Cruz D, Keser G, Khamashta MA, Direskeneli H, Targoff IN, Miller F, Hughes GRV. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol 2000;27:161-164.
62. De Bleeker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994;53:369-376.
63. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000;12:1329-1335.
64. Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis. Arthritis Rheum 1979;22:1088-1092.
65. Drachman DA. Neurological complications of Wegener's granulomatosis. Arch Neurol 1963;8:145-155.
66. Dressell A, Beuche W. Interferon beta-1a treatment of corticosteroid sensitive polymyositis. J Neurol Neurosurg Psychiatry 2002;72:676.
67. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash T, Shemesh M, Sadeh M, Grabov-Nardini G, Shmilevich I, Friedmann A, Karpati G, Bradley WG, Baumbach L, Lancet D, Asher EB, Beckmann JS, Argov Z, Mitrani-Rosenbaum S, The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-87.
68. Elliott JF, Lin Y, Mizel SB, Spector S, Sivakumar K, Cupler E. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 1984;226:1439-1441.
69. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-358.
70. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipe-stem capillaries, microvascular deposition of the complement membrane attack complex (MAC) and minimal cellular infiltration. Neurology 1991;41:936-939.
71. Engel AG, Hohlfeld R, Banker BQ. Inflammatory myopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology, 2nd ed. New York: McGraw-Hill; 1994. p 1335-1383.
72. Engel WK, Askanas V. Treatment of inclusion body myositis and hereditary inclusion body myopathy with reference to pathogenic mechanisms: personal experience. In: Askanas V, Serratrice C, Engel WK, editors. Inclusion body myositis and myopathies. Cambridge: Cambridge University Press; 1998. p 351-382.
73. Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993;20:1340-1344.
74. Fam AG. Recent advances in the management of adult myositis. Expert Opin Invest Drugs 2001;10:1265-1277.
75. Fedczyna TO, Lutz J, Pachman LM. Expression of TNF-alpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol 2001;200:236-239.
76. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzet PM. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996;184:1313-1318.
77. Finger DR, Plotz PH, Heywood G. Myositis following treatment with high-dose interleukin-2 for malignancy. J Rheumatol 1994;4:752-753.
78. Follansbee WP, Zerbe TR, Medsger TAJ. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993;125:194-198.
79. Foote RA, Kimbrough SM, Stevens JC. Lupus myositis. Muscle Nerve 1982;5:65-68.
80. Fraser DD, Frank JA, Dakalas MC, Miller FW, Hicks JE, Plotz PH. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18:1693-1700.
81. Fyhr I-M, Moslemi A-R, Tarkowski A, Lindberg C, Oldfors A. Limited T-cell receptor V gene usage in inclusion body myositis. Scand J Immunol 1996;43:109-114.
82. Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, Bartoccioni E. Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 1998;10:267-273.
83. Garlepp MJ. Genetics of idiopathic inflammatory myopathies. Curr Opin Rheumatol 1996;8:514-520.
84. Garlepp MJ, Mastaglia FL. Autoantibodies in inflammatory myopathies. Am J Med Sci 2000;319:227-233.
85. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994;98:40-45.
86. Garlepp MJ, Chen W, Tabarias H, Bains M, Brooks A, McCluskey J. Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 1995;102:614-619.
87. Garlepp MJ, Tabarias H, van Bockxmeer FM, Zilko PJ, Laing B, Mastaglia FL. Apolipoprotein Ee4 in inclusion body myositis. Ann Neurol 1995;38:957-959.
88. Garlepp MJ, Blechynden L, Tabarias H, Mastaglia FL. Genetic factors in sporadic inclusion body myositis. In: Askanas V, Serratrice G, Engel WK, editors. Inclusion body myositis and myopathies. Cambridge: Cambridge University Press; 1998. p 177-185.
89. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestation of dermatomyositis: a series of four cases. J Rheumatol 2000;27:1542-1545.
90. Genge A, Karpati G. Intermittent, high dose, intravenous glucocorticoid (GC) treatment (Rx) is preferred to high dose oral GC administration in adult dermatomyositis (DM). Neurology 1997;48:A321.
91. Gherardi RK, Coquet M, Cherin P, Authier FJ, Laforet P, Belec L, Figarella-Branger D, Mussini JM, Pellissier JF, Fardeau M. Macrophagic myofasciitis: an emerging entity. Lancet 1998;352:347-352.
92. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001;124: 1821-1831.
93. Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A, Miller FW. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum 1998;41:400-405.
94. Giordano N, Sensi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1601.
95. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R. Differential expression of perforin in muscle-infiltrating T-cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-2910.
96. Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIg) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000;10:29-35.
97. Grau JM, Miro O, Pedrol E, Casademont J, Masanes F, Herrero C, Haussman G, Urbano-Marquez A. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996; 23:1921-1926.
98. Griggs RC, Karpati G. The pathogenesis of dermatomyositis. Arch Neurol 1991;48:21-22.
99. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713.
100. Grob JJ, Collet AM, Bonerandi JJ. Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents. Dermatologica 1989;178:58-59.
101. Group TJDDACS. Development of validated disease activity and damage indices for thejuvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999;42:2213-2219.
102. Group TMS. Randomized pilot trial of beta INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57: 1566-1570.
103. Harvey JM, Mastaglia FL, Zilko PJ, Ojeda VJ, Cheah PS. Scleromyxedema and inflammatory myopathy: a clinico-pathologic study of three patients. Aust NZ J Med 1986;16:329-335.
104. Hausmanowa-Petrusewicz I, Blaszczyk M, Kowalska-Oledzka E, Jablonska S. Scleromyositis a distinctive overlap syndrome. Acta Myol 2000;19:201-204.
105. Heckmatt J, Saunders C, Peters AM, Rose, M, Hasson N, Thompson N, Cambridge G, Hyde SA, Dubowitz V. Cyclosporin in juvenile dermatomyositis. Lancet 1989;1:1063-1066.
106. Hengstman G, Van Den Hoogen F, Van Engelen B, Barrera P, Netea M, Nijmegan LVP. Anti-TNF blockade with Infliximab in polymyositis and dermatomyositis. Arthritis Rheum 2000; 43(suppl 1):S193.
107. Hengstman GJD, Van Engelen BGM, Ter Laak HJ, Gabreels-Feston AAWM. Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy. J Neurol 2000;415:882-884.
108. Hengstman GJD, Ter Laak HJ, Van Engelen BGM. Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone. J Neurol Neurosurg Psychiatry 2001;70:702-710.
109. Henricksson KG, Lindvall B. Polymyositis and dermatomyositis 1990 - diagnosis, treatment and prognosis. Prog Neurobiol 1990;35:181-193.
110. Henricksson KG, Sandstedt P. Polymyositis - treatment and prognosis. Acta Neurol Scand 1982;65:280-300.
111. Hermann DN, Blaivas M, Wald JJ, Feldman EL. Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma. Muscle Nerve 2000;23:1133-1136.
112. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990;322: 869-873.
113. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
114. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12:501-508.
115. Hohlfeld R, Engel AG, Goebels N, Behrens L. Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 1997;9:520-526.
116. Hollingsworth PN, Garlepp MJ, Dawkins RL. Autoimmune diseases of muscle. In: Rose NR, Mackay I, editors. The autoimmune diseases, 3rd ed. San Diego: Academic Press; 1998. p 663-686.
117. Horber FF, Schiedegger JR, Grunig BE, Frey FJ. Thigh muscle mass and function in patients treated with glucocorticoids. Eur J Clin Invest 1985;15:302-307.
118. Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope 1998;108:1001-1005.
119. Huang JL. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methyl-prednisolone pulse therapy. Clin Exp Rheumatol 1999;17: 621-624.
120. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Highs JE, Plotz PH, Miller FW. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-387.
121. Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996;23:1380-1384.
122. Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 1990;13:949-951.
123. Kalovidouris AE. The role of cytokines in polymyositis: interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells. J Lab Clin Med 1992;120:244-251.
124. Kalovidouris AE, Plotkin Z. Synergistic cytotoxic effect of interferon-gamma and tumour necrosis factor-alpha on cultured human muscle cells. J Rheumatol 1995;322:1698-1703.
125. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
126. Koffman B, Amemiya K, Leon-Monzon M, Dakalas MC. Dexamethasone (DEX) induces transcription of glutamine synthetase (GS) in human muscle in vitro: a possible explanation of steroid-induced muscle atrophy ("steroid myopathy"). Neurology 1997;48:A321.
127. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas M. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myositis. J Neuroimmunol 1998;84:139-142.
128. Kok CC, Croager EJ, Witt CS, Kiers L, Mastaglia FL, Abraham LJ, Garlepp MJ. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics 1999;49:508-516.
129. Kok CC, Boyt A, Gaudieri S, Martins R, Askanas V, Dalakas M, Kiers L, Mastaglia F, Garlepp M. Mitochondrial DNA variants in inclusion body myositis and Alzheimer's disease. Neuromuscul Disord 2000;10:604-611.
130. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998;39:899-920.
131. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962;267:1357-1358.
132. Layzer RB, Shearn MA, Satya-Murti S. Eosinophilic polymyositis. Ann Neurol 1977;1:65-71.
133. Leff RL, Miller FW, Hicks JE, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993;72:225-235.
134. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta GP, Pellissier JR. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24:73-79.
135. Liang Y, Inukai A, Kuru S, Kato T, Doyu M, Sobue G. The role of lymphotoxin in pathogenesis in polymyositis. Acta Neuropathol (Berl) 2000;100:521-527.
136. Lindberg C, Oldfors A, Hedstrom A. Inclusion body myositis: peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves. J Neurol Sci 1990;99:327-338.
137. Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-131.
138. Lindberg C, Oldfors A, Trysberg E, Tarkowski A. Anti-thymocyte globulin treatment in inclusion body myositis: a randomised pilot study. Neuromuscul Disord 1999;9:476.
139. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JR, Lepidid H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol 1999;97:642-648.
140. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-374.
141. Luciano CA, Dakalas MC. Inclusion body myositis: no evidence for a neurogenic component. Neurology 1997;48:29-33.
142. Luek CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991;14:304-305.
143. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000;2:216-224.
144. Lundberg IE, Chung Y-L. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatology 2000;39:7-17.
145. Lundberg IE, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:865-874.
146. Maeda K, Kimura A, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997;26:24-29.
147. Mahowald ML. The benefits and limitations of a physical training program for patients with inflammatory myositis. Curr Rheumatol Rep 2001;3:317-324.
148. Maillard SM, Wilkinson NMR, Beresford MW, Davidson JE, Murray KJ. The treatment of persistent severe idiopathic inflammatory myositis with anti-TNF therapy. Ann Rheum Dis 2002;61 (suppl 1):S143.
149. Mantegazza R, Bernasconi P, Confalonieri P, Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J Neurol 1997;244:277-287.
150. Manzur AY, Topaloglu H, Jungbluth H, Dubowitz V, Muntoni F. Cyclosporin treatment in juvenile dermatomyositis: a review of 26 cases. Muscle Nerve 1998;(suppl 7):S150.
151. Marguerie C, Bunn CC, Bevnon HLC, Bernstein RM, Hughes JMB, So AK, Walport MJ. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. QJ Med 1990;282:1019-1038.
152. Marie I, Hatron PY, Hachulla E, Wallaert B, Michon-Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25:1336-1343.
153. Mastaglia FL. Inflammatory diseases of muscle. Oxford: Blackwell Scientific Publications; 1988. 203 p.
154. Mastaglia FL. Treatment of autoimmune inflammatory myopathies. Curr Opin Neurol 2000;13:507-509.
155. Mastaglia FL, Ojeda VJ. Inflammatory myopathies: Part 1. Ann Neurol 1985;17:215-227.
156. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 2002;28:1-20.
157. Mastaglia FL, Walton JN. Inflammatory myopathies. In: Mastaglia FL, Walton JN, editors. Skeletal muscle pathology, 2nd ed. Edinburgh: Churchill Livingstone; 1992. p 453-491.
158. Mastaglia FL, Laing B, Zilko PJ. Treatment of inflammatory myopathies. In: Mastaglia FL, editor. Inflammatory myopathies. London: Bailliere Tindell; 1993. p 717-740.
159. Mastaglia FL, Phillips BA, Zilko PJ. Treatment of inflammatory myopathies. Muscle Nerve 1997;20:651-664.
160. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998;65:107-110.
161. Mastaglia FL, Phillips BA, Zilko PJ. Inflammatory myopathy. Curr Treat Opt Neurol 1999;1:263-272.
162. Mastaglia FL, Phillips BA, Zilko PJ, Garlepp MJ. Relapses in idiopathic inflammatory myopathies. Muscle Nerve 1999;22:1160-1161.
163. Mastaglia FL, Phillips BA, Kok CC, Garlepp MJ. Sporadic inclusion body myositis: clinical and genetic studies. Acta Myol 2000;19:105.
164. Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994;57:1008.
165. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with b-amyloid [25-35]. J Neuroimmunol 1999;93:45-52.
166. Medsger TA, Rodnan GP, Moossy J, Vester JW. Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968;11:554-568.
167. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970;48:715-723.
168. Megens-de Letter M-A, Visser LH, van Doorn PA, Savelkoul HFJ. Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy. Eur Cytokine Netw 1999;10:471-477.
169. Menard DB, Haddad H, Blain JG, Beaudry R, Devroede G, Masse S. Granulomatous myositis and myopathy associated with Crohn's colitis. N Engl J Med 1976;295:818-819.
170. Mendell JR, Garcha TS, Kissel JT. The immunopathogenic role of complement in human muscle disease. Curr Opin Neurol Neurosurg 1996;9:226-234.
171. Mierau R, Dick T, Bartz-Bazzanella P, Keller E, Albert ED, Genth E. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA DR beta chain. Arthritis Rheum 1996;39:868-876.
172. Miller F, Walsh Y, Saminaden S, Lecky B, Winer J. Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002; 199(suppl 1):S53.
173. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993; 270:1846-1849.
174. Miller FW, Rider LG, Chung Y-L, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-1273.
175. Mimori T. Structures targeted by the immune system in myositis. Curr Opin Rheumatol 1996;8:521-527.
176. Miro O, Laguna M, Grau JM. Relapses in idiopathic inflammatory myopathies. Muscle Nerve 1999;22:1159-1160.
177. Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989;2:1454-1455.
178. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-122.
179. Mozaffar T, Lopate G, Pestronk A. Clinical correlates of granulomas in muscle. J Neurol 1998;245:519-524.
180. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibers. J Neurol Neurosurg Psychiatry 2000;68:472-478.
181. Mukunda BN, Kumar PD, Smith HR. Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis. Ann Intern Med 2001;134:1156.
182. Mutsuya M, Abe T, Yonezawa K, Ono A, Ikeda N, Yoshida Y, Akahonai Y, Kurokawa S, Hayashi T. The first case of polymyositis associated with interferon therapy. Intern Med 1994;33:806-808.
183. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz PH. A variety of cytokines and immunologically relevant surface molecules are expresssed by normal skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998;113:407-414.
184. Nakayama T, Horiuchi E, Watanabe T, Murayama S, Nakase H. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding by repeated immunoabsorption. J Neurol Neurosurg Psychiatry 2000;68:230-233.
185. Namba T, Brunner NG, Grob D. Idiopathic giant cell polymyositis: report of a case and review of the syndrome. Arch Neurol 1974;31:27-30.
186. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, Kita Y, Kawai M, Saito Y, Iwamoto I. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/ polymyositis: prediction and treatment with cyclosporine. J Rheumatol 1999;26:1527-1533.
187. Nzeusseu A, Brion F, Lefebvre C, Knoops P, Devogelaer JP, Houssiau FA. Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 1999;17:441-446.
188. Nzeusseu A, Durez P, Houssain FA, Devogelaer JP. Successful use of Infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2001;44:S90.
189. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000;12: 492-497.
190. Oddis CV, Conte CG, Steen VD, Medsger TA. Incidence of polymyositis-dermatomyositis: a 20 year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990;17:1329-1334.
191. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-1217.
192. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-1763.
193. O'Hanlon TP, Dalakas M, Plotz PH, Miller FW. The ab T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994;7:321-333.
194. Oldfors A, Lindberg C. Inclusion body myositis. Curr Opin Neurol 1999;12:527-533.
195. Orth M, Tabrizi SJ, Schapira AHV. Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology 2000;55:1235.
196. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, Gweanter HL, Jerath R, Lang BA, Sinacore J, Szer IS, Dyer AR, Hochberg MC. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998;25:1198-1204.
197. Pachman LM, Liotta-Davis MR, Hong DK, Kensella TR, Mendez EP, Kinder JM, Chen EH. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumour necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-2377.
198. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001;3:334-345.
199. Patrick M, Buchbinder R, Jolley D, Dennett X, Buchanan R. Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering. J Rheumatol 1999;26: 1094-1100.
200. Pautas E, Cherin P, Piette JC, Pelletier S, Wechsler B, Cabane J, Herson S. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol 2000; 18:241-244.
201. Peng ABS, Koffman BM, Malley JD, Dalakas M. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000;55:296-298.
202. Peng JC, Sheem TS, Hzu MM. Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995;121:1298-1301.
203. Phillips BA, Mastaglia FL. Exercise therapy in patients with myopathy. Curr Opin Neurol 2000;13:547-552.
204. Phillips BA, Zilko PJ, Garlepp MJ, Mastaglia FL. Freqency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 1998;21:1668-1672.
205. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-972.
206. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in sporadic inclusion body myositis. A clinical and MRI study. Muscle Nerve 2001;24:1526-1534.
207. Phillips BA, Martin C, Guthrie A, Collins S, Byrne E. The effect of resisted exercise on muscle strength in patients with myopathy. J Neurol Sci 2002;199(suppl 1):S46.
208. Phillips BA, Zilko PJ, Garlepp MJ, Mastaglia FL. Seasonal occurrences of relapses in inflammatory myopathies: a preliminary study. J Neurol 2002;249:441-444.
209. Pickering MC, Walport MJ. Eosinophilic myopathic syndromes. Curr Opin Rheumatol 1998;10:504-510.
210. Prayson RA. Granulomatous myositis: clinicopathologic study of 12 cases. Am J Clin Pathol 1999;112:63-68.
211. Ramirez G, Asherson RA, Khamashta MA, Cervera R, D'Cruz D, Hughes. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990;20:114-120.
212. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, Bernstein BH. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997;24:2436-2443.
213. Reimers CD, Finkenstaedt M. Muscle imaging in inflammatory myopathies. Curr Opin Rheumatol 1997;4:475-485.
214. Reimers CD, Schedel H, Fleckenstein JL, Nagele M, Witt TN, Pongratz DE, Vogl TJ. Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 1994;241:306-314.
215. Ringel SP, Forstot JZ, Tan EM, Wehling C, Griggs RC, Butcher D. Sjogren's syndrome and polymyositis or dermatomyositis. Arch Neurol 1982;39:157-163.
216. Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966; 89:747-768.
217. Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001;57:548-550.
218. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58:1081-1087.
219. Saadeh CK. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum 2000;43(suppl):S193.
220. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992;19:1385-1389.
221. Schneider C, Gold R, Schafers M, Tokya KV. Mycophenolate mofetil in the therapy of refractory polymyositis. Muscle Nerve 2002;25:286-288.
222. Sekul EA, Chow C, Dakalas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1997;48:863-866.
223. Selva-O'Callaghan A, Sanchez-Sitjes L, Munoz-Gall X, Mijares-Boeckh-Behrens T, Solans-Laque R, Angel Bosch-Gil J, Morrell-Brotad F, Vilardell-Tarres M. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology 2000;39:914-916.
224. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2000;12:482-491.
225. Sharp GC, Irvin WS, Tan EW, Gould RG, Holman HR. Mixed connective tissue disease - apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-159.
226. Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975;88:70-86.
227. Simmons Z, Towfighi J. Sporadic inclusion body myositis and hereditary inclusion body myopathy. J Clin Neuromuscul Dis 2002;3:122-132.
228. Souedin SA, Dakalas MC. Treatment of inclusion body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
229. Spector SA, Lemmer JT, Koffman BM, Fleisher TA, Feuerstein IM, Hurley BF, Dalakas MC. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 1997;20:1242-1248.
230. Stonecipher MR, Jorizzo JL, Monu J, Walter F, Sutej PG. Dermatomyositis with normal muscle enzyme concentrations. A single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound. Arch Dermatol 1994;130:1294-1299.
231. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M, Kamatani N. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15 and monocyte chemoattractant protein-1 production. J Immunol 2000;164:6593-6600.
232. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002;41:22-26.
233. Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Pediatr Neurol 1998;2: 205-211.
234. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-674.
235. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000;12:475-481.
236. Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997;9:527-535.
237. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990;141:727-733.
238. Turk L, Poulder LW. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol 1972;10:285-296.
239. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-457.
240. Van der Meulen MF, Hoogendijk JE, Wokke JH, de Visser M. Oral pulsed high-dose dexamethasone for myositis. J Neurol 2000;247:102-105.
241. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, Nemcova D, Charvat F. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102.
242. Villalba L, Adams EM. Update on therapy for refractory dermatomyositis and polymyositis. Curr Opin Rheumatol 1996;8:544-551.
243. Villaba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW. Treatment of refractory myositis. Arthritis Rheum 1998;41:392-399.
244. Walker GL, Mastaglia FL, Roberts DF. A search for genetic influence in idiopathic inflammatory myopathy. Acta Neurol Scand 1982;66:432-443.
245. Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28.
246. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine 1994;73:153-160.
247. Whitmore SE, Watson R, Rosenshein NB, Provost TT. Dermatomyositis sine myositis: association with malignancy. J Rheumatol 1996;23:101-105.
248. Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, Graninger W. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998;37:196-200.
249. Wiesinger GF, Quittan M, Nuhr M, Volc-Platzer B, Ebenbichler G, Zehetgruber M, Graninger W. Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil 2000;81:1-5.
250. Wiles CM, Zarni Y, Nichlin J. Laboratory testing of muscle function in the management of neuromuscular disease. J Neurol Neurosurg Psychiatry 1990;53:384-387.
251. Wintzen AR, Bots GTAM, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry 1988;51:1542-1545.
252. Yazici Y, Kagen LJ. The association of malignancy with myositis. Curr Opin Rheumatol 2000;12:498-500.
253. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-1859.
254. Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996;23:1424-1427.
255. Zilko PJ. Myopathy in connective tissue disease other than polymyositis. In: Mastaglia FL, editor. Inflammatory diseases of muscle. Oxford: Blackwell Scientific Publications; 1988. p 107-124.
256. Zilko PJ, Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies. BioDrugs 1997;7:262-272.